Jupiter Neurosciences (JUNS) Financials

Jupiter Neurosciences (NASDAQ:JUNS) remains in an early commercial stage, with limited revenue and continued operating losses. The company reported $18,652 of revenue in Q1 2026, down from $21,796 in Q4 2025 but up from zero in the first three quarters of 2025. Gross profit was $14,290, representing a strong 76.6% gross margin, although revenue was not sufficient to offset operating expenses.

Operating expenses declined to $1.98 million in Q1 2026 from $2.83 million in Q4 2025. Selling, general and administrative expense fell substantially to $1.57 million, while research and development expense increased to $411,049 from $43,684 in the prior quarter. Despite the lower overall expense base, the company posted a net loss of $2.06 million, or $0.06 per share, compared with a $2.58 million loss in Q4 2025.

Cash flow remains a significant concern. JUNS used $1.43 million in operating cash during Q1 2026, an improvement from the $2.37 million used in Q4 2025 but still representing a substantial quarterly burn rate. The company generated virtually no financing cash during the quarter and had no investing cash flow. Based on the Q1 operating burn, its $2.36 million of cash and equivalents would cover approximately 1.6 quarters of operations before considering debt payments or additional capital needs.

The balance sheet also weakened materially. Cash increased from Q3 2025 to Q1 2026 following $5.58 million of debt issuance in Q4, but short-term debt rose to $4.82 million from $146,432 in Q3. Total current liabilities of $6.73 million were nearly twice current assets of $3.41 million, producing a current ratio of approximately 0.5. Total shareholders’ equity turned negative at $2.78 million, compared with positive equity of $57,417 in Q3 2025.

• Revenue has begun to emerge: Q1 2026 revenue of $18,652 followed $21,796 in Q4 2025, whereas revenue was zero in the earlier reported quarters provided.
• Gross margin was strong: Q1 gross profit of $14,290 on $18,652 of revenue equates to a 76.6% gross margin, although the small revenue base makes this metric difficult to generalize.
• Quarterly losses and operating cash burn improved sequentially: Net loss narrowed to $2.06 million from $2.58 million in Q4 2025, while operating cash outflow improved to $1.43 million from $2.37 million.
• Operating expenses declined sequentially: Total operating expenses fell approximately 30% from Q4 2025, primarily because of lower SG&A spending.
• Research and development spending increased: R&D expense rose to $411,049 from $43,684 in Q4 2025, which could support product development but also increases near-term cash requirements.
• Noncash adjustments remain material: Q1 operating cash flow benefited from $630,057 of noncash adjustments and $189,041 of amortization, so cash usage remains the more important measure of liquidity.
• Revenue remains extremely small relative to expenses: Q1 revenue covered less than 1% of operating expenses, leaving JUNS dependent on outside capital while it develops its business.
• Liquidity is tight: The company held $2.36 million in cash at March 31, 2026, against a Q1 operating cash burn of $1.43 million and $4.82 million of short-term debt.
• Working-capital coverage is weak: Current liabilities of $6.73 million exceeded current assets of $3.41 million, and shareholders’ equity was negative $2.78 million.
• Share dilution is a continuing risk: Basic weighted-average shares increased to 35.3 million in Q1 2026 from 26.5 million in Q1 2024, an increase of roughly 33%, while additional financing may be needed.

Overall, the statements show early signs of revenue generation and sequential improvement in expenses and losses, but JUNS has not yet demonstrated a self-sustaining business model. Retail investors should closely monitor revenue growth, operating cash burn, debt repayment or refinancing plans, and whether future capital raises create further dilution.